RAPP · Rapport Therapeutics, Inc.
$43.62
+0.37% last session
End-of-day data · close of 2026-09-11
Market cap
$2B
Enterprise value
$2B
Trailing P/E
—
Forward P/E
-8.3
Dividend yield
—
Beta
1.03
Avg volume
0M
Employees
0K
Daily Change %
0.37%
5 Days Change
-4.12%
10 Days Change
-9.83%
30 Days Change
-10.11%
60 Days Change
5.11%
Month to Day Change
-9.63%
Year to Day Change
44.64%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — RAPP
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-08-19
Latest call per bank · past 12 months
Wells Fargo
Overweight$46.00
+5.8% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-19 | BTIG | Reiterates | Buy | $65.00 |
| 2026-08-12 | HC Wainwright & Co. | Maintains | Buy | $40.00 → $66.00 |
| 2026-08-05 | BTIG | Reiterates | Buy | $65.00 |
| 2026-07-16 | BTIG | Reiterates | Buy | $65.00 |
| 2026-06-24 | Leerink Partners | Initiates | Outperform | $0.00 → $52.00 |
| 2026-05-21 | BTIG | Maintains | Buy | $53.00 → $65.00 |
| 2026-05-08 | BTIG | Reiterates | Buy | $53.00 |
| 2026-04-22 | BTIG | Reiterates | Buy | $53.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-09-11
- RSI (14): RSI is 39 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 2.2% below the 50-day MA ($44.60).
- Price vs 200-day MA: Trading 24.1% above the 200-day MA ($35.16).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-0.97) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($23.20) and high ($52.50).
RAPP Price Chart
Loading chart for RAPP…
Fundamentals
About Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. It also develops nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and migraine; and a9a10 nAChR for the treatment of hearing/vestibular disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$130B 14.9% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$82B 5.0% YTD
ARGX
argenx SE
$62B 19.2% YTD
MRNA
Moderna, Inc.
$55B 359.9% YTD
RVMD
Revolution Medicines, Inc.
$44B 160.7% YTD
ONC
BeOne Medicines Ltd.
$39B 15.5% YTD
RPRX
Royalty Pharma plc
$34B 59.0% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$33B -35.1% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.